# FDA Inspection 1224780 - Bristol-Myers Squibb Cruiserath Biologics - September 26, 2023

Source: https://www.keypedia.com/records/fda_inspections/bristol-myers-squibb-cruiserath-biologics/376051b2-ea45-4d65-bba8-2bcca5dea87f
Source feed: FDA_Inspections

> FDA Inspection 1224780 for Bristol-Myers Squibb Cruiserath Biologics on September 26, 2023. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1224780
- Company Name: Bristol-Myers Squibb Cruiserath Biologics
- Inspection Date: 2023-09-26
- Classification: No Action Indicated (NAI)
- Project Area: Drug Quality Assurance
- Product Type: Drugs
- Office Name: Center for Drug Evaluation and Research

## Related Documents

- [FDA Inspection 1067641 - 2018-07-04](https://www.keypedia.com/records/fda_inspections/bristol-myers-squibb-cruiserath-biologics/998a3504-abbd-4825-906c-f00a3f209b65)
- [FDA Inspection 982749 - 2016-07-12](https://www.keypedia.com/records/fda_inspections/bristol-myers-squibb-cruiserath-biologics/e4d56b6f-c25f-4fd4-a899-8d79c1de9261)
- [FDA Inspection 800401 - 2012-09-06](https://www.keypedia.com/records/fda_inspections/bristol-myers-squibb-cruiserath-biologics/1ea34ae0-500c-405e-b1e0-0c6585be08e3)

Company: https://www.keypedia.com/companies/bristol-myers-squibb-cruiserath-biologics/957f18de-7931-4cb2-a5ce-48d3a195ec6e

Office: https://www.keypedia.com/offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c